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1718-21 Functional Effects of TNFa Gene Expression in the
Heart
Samir Kapadia, Joseph Lee, Guillermo Torre-Amione, Tony S. Ma, Douglas
L. Mann. VAMC & Baylor Coli. of Med, Houston, 7X
TNFa, a proinflammatory cytokine, has been implicated in the pathogene-
sis of septic shock, viral myocarditis, and congestive heart failure. While
the activated macrophage is thought to be the 10 source for TN Fa produc-
tion, a recent report showed that TNFa mRNA was expressed in the heart.
However, the significance of this finding is not known. Accordingly, the pur-
pose of this study was to determine: (1) which cell types in the heart pro-
duce TNFa mRNA and protein; and (2) whether the TNFa which is produced
is active biologically. Protocol: we stimulated isolated, buffer perfused cat
hearts (n = 8) with lipopolysaccharide (LPS) - a classical stimulus for TNFa
production; control hearts (n = 5) were stimulated with diluent. Northern
blot analysis showed that mRNA for TNFa was detected within 30 min and
peaked at 90 min after LPS stimulation; mRNA forTNFa was not detectable
in control hearts. TNFa protein (>500 U/ml) was detectable by bioassay 60
min after LPS treatment and peaked by 120 min; TNFa protein was not
detectable in control hearts. TNFa contained in the effluent (1:2 dilution)
from the LPS treated hearts produced negative inotropic effects in isolated
contracting feline cardiac myocytes. Immunohistochemical studies of LPS
treated hearts localized TNFa to the cardiac myocytes, endothelial cells and
to vascular smooth muscle cells; control hearts were negative for TNFa im-
munostaining. Subsequent studies employing myocytes and non-myocyte
cell types isolated from LPS stimulated hearts showed that TNFa mRNA and
protein were produced by myocytes and non-myocytes. Conclusion: these
data show for the first time that myocyte and non-myocyte cell types in the
heart can rapidly produce biologically active TNFa which is capable of caus-
ing negative inotropic effects.
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1718-31 Cardiac Overexpression of pARK in Transgenic Mice
Inhibits Isoproterenol Stimulated Contractility In Vivo
Howard A. Rockman, RaeAnn Hamilton, Carmela A. Milano, Lan Mao, Robert
J. Lefkowitz, Walter J. Koch. HHMI, Duke University, Durham, NC; University of
California, San Diego, La Jolla, CA
Heart failure is associated with a desensitization to ,/l-adrenergic receptor
(,/l-AOR) stimulation which may contribute to the loss of cardiac contractility.
This may be due, in part, to receptor uncoupling through phosphorylation of
agonist occupied receptor by the ,/l-adrenergic receptor kinase (,/lARK). Al-
though recent studies have shown increased expression of ,/lARK in human
heart failure, it is unknown whether enhanced expression of ,/lARK would
result in desensitization in the normal heart. Accordingly, transgenic mice
were generated which overexpress ,/lARK (3-5 fold increase) targeted to the
heart with the aMHC promoter. In vivo hemodynamic parameters were ob-
tained in anesthetized intact transgenic (n = 10) and control (n = 8) mice
using a 2F high fidelity micromanometer placed in the left ventricle (LV) at
baseline and after progressive doses of isoproterenol (ISO) (0.005 to 1ng).
Baseline LV dP/dtmax (control 3824 ± 327, transgenic 3594 ± 308, mmHg/s,
p = ns, mean ± SEM) and heart rate (control 370 ± 15, transgenic 343 ± 15,
beatslmin, p = ns) were similar in both groups. In contrast. overexpression
of ,/lARK significantly inhibited the rise in LV dP/dtmax with ISO (1 ng) (control
8410 ± 678, transgenic 6284 ± 645 mmHg/s, p < 0.05). The ISO stimulated
increase in heart rate was also significantly blunted in the transgenic group
(control 430 ± 20, transgenic 376 ± 12 beatslmin, p < 0.05). No difference
in LV pressure between groups was seen with ISO infusion.
In conclusion, cardiac overexpression of ,/lARK had no effect on basal con-
tractility but significantly impaired the inotropic and chronotropic response
to ISO. This suggests that in the normal heart, receptor occupancy by agonist
is a required process for in vivo ,/l-AOR desensitization.
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Lack of Positive Inotropic Effect by p-Adrenoceptor
Stimulation in the Failing Myocardium is not Due to
Inability to Supply Intracellular Ca2+ nor cAMP:
Studies in Dahl Rat Heart Failure Model
Moriaki Inoko, Yasuk, Kihara, Shigetake Sasayama. Third Division, Department of
Internal Medicine, Kyoto University Faculty of Medicine, Kyoto. Japan
We recently reported that the Dahl salt-sensitive rat (OS) fed with a high-
salt diet presents the transition from compensatory LV hypertrophy at the
age of 11 weeks (LVH) to the decompensated LV dilatation at the age of 16-
22 weeks (CHF). To investigate the mechanisms of decreased positive in-
otropic effects of ,/l-adrenoceptor stimulation in the failing myocardium, we
observed the effects of isoproterenol (ISO) (1 0-9_1 0-6M) and forskolin (FORI
(10-7-1 0-5M) on the isometric tension (T) and the corresponding intracel-
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lular calcium transients (Ca~+) in the aequorin-Ioaded LV papillary muscles
from this animal. Control studies were performed in 18-week-old Dahl salt-
resistant rats (DR). In LVH, OS showed a significant prolongation in the time
course of T without changes in that of Cat+. In CHF, peak T was depressed
and the time course of T was further prolonged, which was accompanied
by a reduced amplitude and a prolonged time course of Cat+ The positive
inotropic effect (increase in peak T) by ISO was decreased in LVH and disap-
peared in CHF despite preserved augmentation of peak CaF+ in both stages.
In contrast, FOR increased both peak T and peak CaF+ in either stage.
ISO 110-5 M) ISO 110-5 M) FOR110- 5 M) FOR (10-5 M)
%peakT %peakCaf+ %peakT %peakCaf+
DR 6 189 ± 34 202 ± 36 284 ± 72 301 ± 69
LVH OS 6 146 ± 21' 182 ± 32 196± 17' 282 ± 43
CHF DS 6 83 ± 24'" 158±21' 173 ± 52' 248 ± 44
means ± S.D.; %peakT: %change in peakT; %peakCa~+: %change in peakCa~+; *p <
005, "p < 001 vs. DR. t P < 0.05, 'p < 0.01 vs. LVH DS
Conclusions: Intracellular calcium handling was altered considerably dur-
ing the transition from LVH to CHF. However, the discrepancy between the
inotropic effect by ISO and that by FOR in CHF was not due to inability to
supply Ca2+ for myofilaments. The results suggest ISO-specific desensitiza-
tion of myofilaments for Ca2+ in CHF muscle, which may be mediated by
,/l-receptor/G-protein systems but not by adenylate cyclase activation.
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Differential Regulation of Phosphorylase Kinase in
Failing Human Left Ventricular Myocardium
Glenn E. Meixell, Wendy P. Wangsgaard, Donald K. Blumenthal, Michael
R. Bristow. University of Colorado Health Sciences Center. Denver. Colorado
Congestive heart failure is characterized by a hyperadrenergic state and in-
creased intracellular Ca++ levels in failing human ventricular myocardium.
Phosphorylase kinase is a key enzyme in the ,/l-adrenergic pathway and is
primarily regulated by cyclic AMP dependent protein kinase and calcium. In
the case of phosphorylase kinase in failing human heart, an increase in ,/l-
adrenergic drive and intracellular Ca++ would be expected to increase the
rate of glycogenolysis, leading to a depletion of glycogen. However, glyco-
gen stores appear to increase in failing as compared to nonfailing human left
ventricular myocardium (unpublished observations). Therefore, we tested
the hypothesis that in heart failure, the hyperadrenergic state results in dif-
ferential regulation of phosphorylase kinase in failing human ventricular my-
ocardium. An enzymatic assay of [y_32pJ ATP was used to measure the rate
of incorporation of 32p into the endogenous substrate of phosphorylase ki-
nase, phosphorylase b. We have shown that phosphorylase kinase in crude
extracts from failing (IOC, n = 10) human left ventricular myocardium has a
specific activity (nmol/min·mg) that is twofold higher than in nonfailing (n =
8) left ventricular myocardium (0.09 ± 0.016 vs. 0.22 ± 0.02 nmol/min.mg,
p < ODS'). Moreover, activation of the enzyme in failing heart upon binding
an antibody raised to the N-terminal region of the catalytic subunit results in
higher specific activities than nonfailing heart (DAD ± 0.09 vs. 0.64 ± 0.16
nmol(min·mg, p < 0.05"), suggesting altered function within the regulatory
subunits. These results support the hypothesis that in failing human heart,
phosphorylase kinase is differentially regulated. Moreover, these results in-
dicate that in failing myocardium, other downstream enzymatic processes
in the glycogenolytic pathway may be affected, such as phosphorylase b to
a conversion, which prevent appropriate glycogen turnover under the influ-
ence of increased adrenergic drive.
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1718-61 Immunohistochemical Localization of Growth Factors
in the Human Failing Myocardium
Doris Haab, Patrick Franzen, Mohammad Mehrabi, Karina Plesch, Ingrid Pribill,
Michael Grimm, Hans-Georg Eichler, Gunter Klappacher. University of Vienna,
Vienna, Austria
The expression of growth factors was analysed by immunohistochemistry
in 25 explanted human hearts with endstage cardiomyopathy obtained at
the time of transplantation surgery (12 idiopathic 110 ischemic 13 valvular
heart disease). The aim of this study was to assess the relation between
distribution of growth factors and fibrosis and microvessel formation in the
myocardium. Basic fibroblast growth factor (bFGF) was predominantly lo-
calized in the extracellular matrix, reflected by the significant correlation be-
tween morphometric area fractions of collagen type I and bFGF (R = 0.6,
p < 0.05). In terms of cellular distribution, bFGF was strongly expressed on
vascular smooth muscle cells of small intramural coronary arteries, as de-
tected by double immunostaining with a fluorescence-conjugated antibody
